Latest Intravenous immunoglobulin Stories
Grifols welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State LA President James Rosser, Councilman Hose Huizar, patient representatives and other dignitaries for the construction dedication ceremony of its new IVIG facility. LOS ANGELES, Jan.
Patients with this Pediatric Disease Depend on Plasma Donation ANNAPOLIS, Md., Jan.
Implications for new tests and more personalized treatments for autoimmune diseases
ATLANTA and LACHEN, Switzerland, Dec. 4 /PRNewswire/ -- Octapharma Chairman Wolfgang Marguerre today announced that Dennis D. Curtin has been selected to lead Octapharma's plasma operations in the United States. Curtin had been Octapharma's U.S.
PROVIDENCE, R.I., Oct. 27 /PRNewswire/ -- Dr.
Under a new program introduced by Talecris Biotherapeutics, patients who regularly use Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) may be able to receive continuing treatment in the event of a lapse in private insurance coverage.
Every one in three patients needing a kidney transplant may never receive one because their bodies are unusually conditioned to assault a donated organ. Doctors are now trying to outsmart the immune system and save more "highly sensitized" patients.
A study of a treatment for chronic inflammatory demyelinating neuropathy (CIDP) suggests that 50 percent of the patients who responded to treatment with Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) required two treatments before they first exhibited improvements on a standard disability measurement scale, according to data presented at the American Neurological Association meeting in Salt Lake City, Utah.
The FDA has approved Talecris Biotherapeutics's Gamunex, an immune globulin product for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the legs and arms.
Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted approval for Gamunex (Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified) as a treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).